<DOC>
	<DOCNO>NCT00264797</DOCNO>
	<brief_summary>The purpose study determine efficacy osmotic-release methylphenidate ( OROS-MPH ) versus placebo treatment ADHD adolescents SUD .</brief_summary>
	<brief_title>Attention Deficit Hyperactivity Disorder ( ADHD ) Adolescents With Substance Use Disorders ( SUD )</brief_title>
	<detailed_description>Research show high prevalence Attention Deficit Hyperactivity Disorder ( ADHD ) adolescents substance abuse disorder indicate poor substance use treatment outcome poorer prognosis risk persistence progression drug use behavior problem adulthood . Although research indicate majority treat ADHD substance treatment , know whether concurrent pharmacotherapy ADHD improve treatment outcomes . This Clinical Trials Network ( CTN ) study evaluate efficacy osmotic-release methylphenidate ( OROS-MPH ) , relative placebo , treat ADHD decrease substance use adolescent ( 13-18 year old ) ADHD substance use disorder . Approximately 300 participant recruit 11 site randomly assign either OROS-MPH matching placebo 16-week treatment period , participant receive individual cognitive-behavioral therapy standardize treatment substance abuse .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Meet Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) diagnostic criterion ADHD Meet DSMIV diagnostic criterion least one nonnicotine substance use disorder Has DSMIV ADHD Symptom Checklist score â‰¥ 22 derive adolescentcompleted checklist Serious medical illness History tic disorder Pregnant breastfeed Meet DSMIV criterion current lifetime psychotic disorder Meet DSMIV criterion current lifetime bipolar disorder Requires/or prescribe concurrent psychotropic medication Taking medication may produce interaction OROSMPH Opiate dependence Methamphetamine abuse dependence Suicidal risk Enrolled inpatient , residential , day treatment , outpatient substance abuse program within 28 day prior sign consent</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>